Patents by Inventor Stefanie Dimmeler

Stefanie Dimmeler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120238619
    Abstract: The present invention relates to treating or preventing age-related cardiomyopathy by modulating the expression or activity of a miR-34 family member and/or PNUTS. Methods of treating or preventing age-related cardiomyopathy include administering an inhibitor of miR-34 expression or activity or an agonist of PNUTS expression or activity. Also provided herein are methods of treating or preventing cardiac fibrosis and myocardial infarction by administering an inhibitor of miR-34 expression or activity or an agonist of PNUTS expression or activity.
    Type: Application
    Filed: March 16, 2012
    Publication date: September 20, 2012
    Applicant: Miragen Therapeutics
    Inventors: Stefanie DIMMELER, Reinier A. Boon, Ariane Fischer, Andreas M. Zeiher
  • Patent number: 8258113
    Abstract: The invention relates to a method for influencing the miR-92 expression in a cell, comprising the following steps: (a) providing a cell; and (b1) reducing the miR-92 expression in the cell in order to promote the vascularization or vessel repair by introducing an antisense molecule against miR-92 into the cell, or (b2) increasing the miR-92 expression in the cell for an inhibition of the tumor angiogenesis by introducing a construct into the cell, wherein the construct includes an expressible miR-92 sequence. Furthermore, the invention relates to a pharmaceutical composition, comprising an agent for reducing the miR-92 activity or expression in a cell in the form of an antisense molecule against miR-92, or an agent for increasing the miR-92 expression in a cell in the form of a construct for expressing miR-92.
    Type: Grant
    Filed: October 30, 2008
    Date of Patent: September 4, 2012
    Assignee: t2cure GmbH
    Inventors: Stefanie Dimmeler, Andreas M. Zeiher, Angelika Bonauer, Carmen Urbich
  • Patent number: 7919315
    Abstract: The present invention relates to an in vitro method for the analysis of a sample from a mammal in connection with cardiovascular diseases, wherein the method comprises the following steps: a) isolating of bone marrow-precursor cells (BMPs) and/or blood-derived circulating precursor cells (BDPs) by means of cell specific surface markers, and b) detecting the cardiovascular functionality of the isolated BMPs and/or BDPs by means of a suitable migration assay. The method according to the invention can be employed as a kit in the context of the diagnosis and/or the prognosis of cardiovascular diseases, for the monitoring of their therapies and/or for a stratification for a prospective cell therapy with stem- and/or precursor cells in order to increase the perfusion of ischemic tissue or for a regeneration of tissue losses (e.g. heart insufficiency), respectively.
    Type: Grant
    Filed: October 13, 2004
    Date of Patent: April 5, 2011
    Assignee: T2Cure GmbH
    Inventors: Andreas M. Zeiher, Christopher Heeschen, Stefanie Dimmeler
  • Publication number: 20100324118
    Abstract: The invention relates to a method for influencing the miR-92 expression in a cell, comprising the following steps: (a) providing a cell; and (b1) reducing the miR-92 expression in the cell in order to promote the vascularization or vessel repair by introducing an antisense molecule against miR-92 into the cell, or (b2) increasing the miR-92 expression in the cell for an inhibition of the tumor angiogenesis by introducing a construct into the cell, wherein said construct includes an expressible miR-92 sequence. Furthermore, the invention relates to a pharmaceutical composition, comprising an agent for reducing the miR-92 activity or expression in a cell in the form of an antisense molecule against miR-92, or an agent for increasing the miR-92 expression in a cell in the form of a construct for expressing miR-92.
    Type: Application
    Filed: October 30, 2008
    Publication date: December 23, 2010
    Inventors: Stefanie Dimmeler, Andreas M. Zeiher, Angelika Bonauer, Carmen Urbich
  • Publication number: 20100068190
    Abstract: The present invention relates to a medicament comprising a mesoangioblast-like cell obtained from a subject, a method of isolating a mesoangioblast-like cell, a method of producing a mesoderm-derived cell using a mesoangioblast-like cell, the use of a mesoangioblast-like cell for the preparation of a medicament for treating a cardiovascular disease and/or an ischemic disease and a method of converting the mesoangioblast-like cell into a pluripotent stem cell.
    Type: Application
    Filed: June 25, 2009
    Publication date: March 18, 2010
    Applicant: t2cure GmbH
    Inventors: Stefanie Dimmeler, Andreas Zeiher, Masamichi Koyanagi
  • Publication number: 20090155827
    Abstract: The present invention refers to a use of an ex vivo method comprising the determination of PlGF and sFlt-1 in a sample for diagnosis, risk stratification and/or monitoring of a vascular disease with atherosclerotic etiology, in particular a coronary heart disease such a unstable angina pectoris or myocardial infarction, and/or for estimation of the probability of developing such a disease, as well as for identification of a patient supposed to benefit from a therapy by agents reducing the risk for a cardiovascular disease. In the method (i) a ratio of [PlGF=high:sFlt-1=low], and/or (ii) a PlGF concentration in the upper two tertiles of a reference collective, and an sFlt-1 concentration in the lower tertile of the reference collective, and/or (iii) a PlGF result above a PlGF reference value, and an sFlt-1 result below an sFlt-1-reference value indicate an elevated probability for an adverse event. The present invention also refers to the used method.
    Type: Application
    Filed: October 25, 2005
    Publication date: June 18, 2009
    Applicant: DADE BEHRING MARBURG GMBH
    Inventors: Andreas M. Zeiher, Christopher Heeschen, Stefanie Dimmeler
  • Publication number: 20070274959
    Abstract: The present invention relates to an in vitro method for the analysis of a sample from a mammal in connection with cardiovascular diseases, wherein the method comprises the following steps: a) isolating of bone marrow-precursor cells (BMPs) and/or blood-derived circulating precursor cells (BDPs) by means of cell specific surface markers, and b) detecting the cardiovascular functionality of the isolated BMPs and/or BDPs by means of a suitable migration assay. The method according to the invention can be employed as a kit in the context of the diagnosis and/or the prognosis of cardiovascular diseases, for the monitoring of their therapies and/or for a stratification for a prospective cell therapy with stem- and/or precursor cells in order to increase the perfusion of ischemic tissue or for a regeneration of tissue losses (e.g. heart insufficiency), respectively.
    Type: Application
    Filed: October 13, 2004
    Publication date: November 29, 2007
    Inventors: Andreas Zeiher, Christopher Heeschen, Stefanie Dimmeler
  • Publication number: 20070042438
    Abstract: The invention relates to novel markers of vascular inflammation and combinations thereof as diagnostic and prognostic tools in patients with cardiovascular diseases. The markers also act as tools that facilitate the selection of active ingredients for the treatment of such diseases, and finally act as starting points for the treatment of cardiovascular diseases. Furthermore, the invention relates to the creation of an individual risk profile of negative events that are associated with the progression of arteriosclerosis.
    Type: Application
    Filed: November 10, 2003
    Publication date: February 22, 2007
    Inventors: Andreas Zeiher, Christopher Heeschen, Stefanie Dimmeler, Christian Hamm
  • Publication number: 20060246044
    Abstract: Improving cell therapy and tissue regeneration in a patient suffering from a cardiovascular or a neurological disease by treating a tissue of the patient with shock waves and/or applying to the patient a therapeutically effective amount of stem cells and/or progenitor cells. Such treatment increases expression of chemoattractants, pro-angiogenic factors, and pro-survival factors. The chemoattractants can be, for example, vascular endothelial growth factor (VEGF) or stromal cell derived factor 1 (SDF-1). For example, the treated tissue can be located in the patient's heart or in a skeletal muscle of the patient, and the shock waves can be extracorporeal shock waves (ESW) or intracorporeal shock waves. The cardiovascular disease can have an ischemic or non-ischemic etiology. For example, the cardiovascular disease can be a myocardial infarction, ischemic cardiomyopathy, or a dilatative cardiomyopathy. For example, the neurological disease can be a peripheral neuropathy or neuropathic pain.
    Type: Application
    Filed: December 15, 2005
    Publication date: November 2, 2006
    Applicant: Dornier MedTech System GmbH
    Inventors: Andreas Lutz, Harald Eizenhofer, Andreas Zeiher, Stefanie Dimmeler, Christopher Heeschen, Alexandra Aicher
  • Publication number: 20050244897
    Abstract: The invention relates to a method for the immunocytological determination of apoptotic endothelial cells and/or endothelial precursor cells in samples such as, for example, peripheral blood, by means of, for example, throughflow cytometry or by means of a solid-phase immunoassay, as a diagnostic instrument in patients in whom a cardiovascular disease is either manifest or who carry the risk for the same and as an instrument by means of which the prevention and the therapeutic management of such a disease can be improved.
    Type: Application
    Filed: November 17, 2003
    Publication date: November 3, 2005
    Inventors: Andreas Zeiher, Stefanie Dimmeler, Lothar Rossig
  • Publication number: 20050101599
    Abstract: The present invention relates to the use of compounds which enhance the transcription of endothelial nitric oxide synthase (eNOS) for treating stem and progenitor cells in the cell therapy of patients with ischemic heart diseases such as coronary heart disease or ischemic cardiomyopathy. Treatment of such cells which are isolated from bone marrow, for example, with an eNOS transcription enhancer prior to their administration improves their functional activity and ameliorates neovascularization of the heart and cardiac regeneration.
    Type: Application
    Filed: November 2, 2004
    Publication date: May 12, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Andreas Zeiher, Stefanie Dimmeler, Christopher Heeschen, Hartmut Ruetten